Pneumagen

NorthLinks Bio is a clinical-stage biopharmaceutical company developing HEX17, an intranasal antiviral spray designed to provide broad-spectrum protection against respiratory viruses. The platform uses engineered carbohydrate-binding modules (CBMs) to mask host receptors and inhibit viral entry for pathogens including influenza, RSV, and coronaviruses. The company targets the prevention of respiratory tract infections through a host-directed mechanism that maintains activity despite viral evolution.